B Cell Lymphoma
From the Journals
BTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignancies
Success of BTKi in treating lymphoid malignancies is marred by resistance
News from the FDA/CDC
FDA grants zanubrutinib an accelerated approval in marginal zone lymphoma
From the Journals
Can reversing T-cell exhaustion benefit in B-cell lymphoma relapse?
News
FDA approves zanubrutinib in Waldenström’s macroglobulinemia
Latest News
Hematologic cancer increases risk of delivery complications
A new study found that women with current cancer diagnosis have an increased risk of in-hospital complications, compared with women without cancer...
Conference Coverage
Real-world CAR T outcomes for DLBCL mimic clinical trials
Survival and safety outcomes in the monde réel (real world) were comparable with those seen in clinical trials for patients with advanced...
Conference Coverage
Experimental antibody-drug conjugate shown active against r/r DLBCL
From the Journals
Choosing the right R-CHOP dosage for elderly patients with DLBCL
From the Journals
High-dose methotrexate of no CNS benefit for patients with high-risk DLBCL
Conference Coverage
Pediatric cancer survivors at risk for opioid misuse
Conference Coverage
No SPARKLE with ibrutinib plus chemo in r/r pediatric B-NHL